Photo of Eileen Kemether

Eileen Kemether

Print ProfilePrint Profile



  • Psychiatry, American Board of Psychiatry and Neurology


  • MD, Mount Sinai Sch. of Medicine CUNY

  • Residency, Psychiatry
    Mount Sinai School of Medicine

  • Fellowship, Psychiatry
    Pilgrim Psychiatric Center


Dr. Kemether's research interests include:

The study of the transcriptome of cells from various thalamic regions in schizophrenia versus non-psychiatric control postmortem samples.   The comparison of the whole human genome transcriptome of cells from one thalamic region in schizophrenia, bipolar mood disorder, depression versus non-psychiatric controls.  These studies employ laser capture microdissection to isolate the cells for high throughput microarray analysis in collaboration with Dr. Tearina Chu.  We will compare transcriptome findings from medial tier thalamic regions that have been implicated in schizophrenia with a lateral tier nucleus in the same subject.  A large scale qPCR validation study is ongoing. 


Byne W, Hazlett EA, Buchsbaum MS, Kemether E. The thalamus and schizophrenia: current status of research. Acta Neuropathol 2008 July 5; [Epub ahead of print].

Hazlett EA, Buchsbaum MS, Zhang J, Newmark RE, Glanton CF, Zelmanova Y, Haznedar MM, Chu KW, Nenadic I, Kemether EM, Tang CY, New AS, Siever LJ. Frontal-striatal-mediodorsal nucleus dysfunction in schizophrenia-spectrum patients during sensorimotor gating. NeuroImage 2008; 42: 1164-1177.

Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes TR, Mukherjee J. D2/D3 dopamine receptor binding with [F-18] fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 2006; 85: 232-244.

Mitelman SA, Byne W, Kemether EM, Hazlett EA, Buchsbaum MS. Metabolic disconnection between the mediodorsal nucleus of the thalamus and cortical Brodmann's areas of the left hemisphere in schizophrenia. Amer J Psych 2005; 162: 1733-1735.

Lehrer DS, Christian BT, Mantil J, Murray AC, Buchsbaum BR, Oakes TR, Byne WM, Kemether EM, Buchsbaum MS. Thalamic and prefrontal FDG uptake in never-medicated patients with schizophrenia. Amer J Psych 2005; 162: 931-938.

Hazlett EA, Buchsbaum MS, Kemether E, Bloom R, Platholi J, Brickman AM, Shihabuddin L, Tang C, Byne W. Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia. Am J Psych 2004; 161: 305-314.

Kemether EM, Buchsbaum MS, Byne W, Hazlett EA, Haznedar M, Brickman A, Platholi J, Bloom R. Magnetic resonance imaging of mediodorsal, pulvinar and centromedian nuclei of the thalamus in patients with schizophrenia. Arch Gen Psych 2003; 60: 983-991.

Byne W, Buchsbaum MS, Mattiace LA, Hazlett EA, Kemether E, Elhakem SL, Purohit DP, Haroutunian V, Jones L. Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am J Psych 2002; 159: 59-65.

Byne W, Tobet S, Mattiace LA, Lasco MS, Kemether E, Edgar MA, Morgello S, Buchsbaum MS, Jones LB. The interstitial nuclei of the human anterior hypothalamus: an investigation of variation with sex, sexual orientation, and HIV status. Horm Behav 2001; 40: 86-92.

Byne W, Buchsbaum MS, Kemether E, Hazlett E, Shinwari A, Siever L. Magnetic resonance imaging of the mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder. Arch Gen Psych 2001; 58: 133-140.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Kemether did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


903 Park Avenue
Suite 2C
New York, NY 10021

Tel: 212-737-1898

903 Park Avenue
Suite 2C
New York, NY 10021

Tel: 212-737-1898
Fax: 212-737-1898
Get Directions

Office Hours:
  • Monday 9:00am - 6:00pm
  • Tuesday 9:00am - 6:00pm
  • Wednesday 9:00am - 6:00pm
  • Thursday 9:00am - 6:00pm
  • Friday 9:00am - 6:00pm
Insurance Plans
  • Aetna
  • Medicare
  • Oxford Health Plans
  • United Healthcare
Payment Methods
  • Personal Check
  • Cash